Zylox-Tonbridge Medical Technology Co., Ltd. Class H(DE:818)
€2.100.00 (0.00%)
DE:818
Zylox-Tonbridge Medical Technology Co., Ltd. Class H financials statements
€2.10
At close:0.00 (0.00%)
Zylox-Tonbridge Medical Technology Co., Ltd. Class H (818) Ratios
1 Followers
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Ratios
DE:818's free cash flow for Q2 2026 was ¥198.83M. For the 2026 fiscal year, DE:818's free cash flow was decreased by ¥-32.99M and operating cash flow was ¥231.83M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.98 | 4.58 | 5.40 | 13.56 | 31.14 |
| Quick Ratio | 5.41 | 3.96 | 4.83 | 12.78 | 30.55 |
| Cash Ratio | 1.78 | 1.25 | 3.42 | 7.93 | 14.61 |
| Solvency Ratio | 0.82 | 0.37 | -0.13 | -0.55 | -1.83 |
| Operating Cash Flow Ratio | 1.16 | 0.52 | 0.31 | -0.60 | -1.20 |
| Short-Term Operating Cash Flow Coverage | 6.05 | 2.00 | 1.97 | 0.00 | 0.00 |
| Net Current Asset Value | ¥ 1.60B | ¥ 1.18B | ¥ 1.39B | ¥ 1.90B | ¥ 2.92B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.03 | 0.02 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.03 | 0.02 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.03 | 0.02 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.11 | 1.11 | 1.11 | 1.05 | 1.03 |
| Debt Service Coverage Ratio | 3.85 | 0.73 | -0.81 | -129.39 | -634.68 |
| Interest Coverage Ratio | 197.32 | 28.01 | -125.12 | -288.64 | -692.10 |
| Debt to Market Cap | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.20 | 0.29 | 0.17 | 0.04 | 0.03 |
| Net Debt to EBITDA | -2.19 | -5.01 | 24.77 | 13.76 | 6.76 |
| Profitability Margins | |||||
| Gross Profit Margin | 72.14% | 71.55% | 72.95% | 75.63% | 74.13% |
| EBIT Margin | 18.80% | 4.62% | -14.68% | -33.77% | -122.63% |
| EBITDA Margin | 22.32% | 8.34% | -7.88% | -25.91% | -117.18% |
| Operating Profit Margin | 18.59% | 7.78% | -29.66% | -62.38% | -119.43% |
| Pretax Profit Margin | 21.81% | 12.81% | -14.92% | -33.99% | -112.24% |
| Net Profit Margin | 23.11% | 12.81% | -14.92% | -33.99% | -112.24% |
| Continuous Operations Profit Margin | 23.11% | 12.81% | -14.92% | -33.99% | -112.24% |
| Net Income Per EBT | 105.97% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 117.28% | 164.58% | 50.30% | 54.49% | 93.98% |
| Return on Assets (ROA) | 6.84% | 2.90% | -2.33% | -3.49% | -6.15% |
| Return on Equity (ROE) | 7.56% | 3.23% | -2.58% | -3.67% | -6.35% |
| Return on Capital Employed (ROCE) | 6.05% | 1.95% | -5.12% | -6.72% | -6.74% |
| Return on Invested Capital (ROIC) | 5.94% | 1.90% | -5.03% | -6.70% | -6.28% |
| Return on Tangible Assets | 6.91% | 2.93% | -2.34% | -3.54% | -6.20% |
| Earnings Yield | 3.64% | 2.80% | -2.12% | -3.03% | -3.26% |
| Efficiency Ratios | |||||
| Receivables Turnover | 47.55 | 508.43 | 446.49 | 329.48 | 398.91 |
| Payables Turnover | 4.73 | 3.21 | 3.36 | 4.46 | 2.13 |
| Inventory Turnover | 1.58 | 1.08 | 0.78 | 0.68 | 0.80 |
| Fixed Asset Turnover | 1.49 | 1.18 | 0.91 | 1.07 | 0.92 |
| Asset Turnover | 0.30 | 0.23 | 0.16 | 0.10 | 0.05 |
| Working Capital Turnover Ratio | 0.75 | 0.60 | 0.32 | 0.14 | 0.11 |
| Cash Conversion Cycle | 160.89 | 223.91 | 361.90 | 453.83 | 283.96 |
| Days of Sales Outstanding | 7.68 | 0.72 | 0.82 | 1.11 | 0.92 |
| Days of Inventory Outstanding | 230.30 | 336.95 | 469.59 | 534.56 | 454.13 |
| Days of Payables Outstanding | 77.09 | 113.75 | 108.51 | 81.83 | 171.09 |
| Operating Cycle | 237.98 | 337.67 | 470.41 | 535.66 | 455.05 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.17 | 0.54 | 0.30 | -0.28 | -0.39 |
| Free Cash Flow Per Share | 0.83 | -0.05 | -0.28 | -0.72 | -0.70 |
| Dividend Paid and CapEx Coverage Ratio | 2.69 | 0.91 | 0.52 | -0.63 | -1.30 |
| Capital Expenditure Coverage Ratio | 3.48 | 0.91 | 0.52 | -0.63 | -1.30 |
| Operating Cash Flow Coverage Ratio | 5.92 | 1.91 | 1.76 | -6.52 | -12.36 |
| Operating Cash Flow to Sales Ratio | 0.36 | 0.22 | 0.19 | -0.27 | -0.65 |
| Free Cash Flow Yield | 4.00% | -0.48% | -2.50% | -6.32% | -3.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 27.30 | 35.68 | -47.06 | -32.99 | -30.64 |
| Price-to-Sales (P/S) Ratio | 6.35 | 4.57 | 7.02 | 11.21 | 34.39 |
| Price-to-Book (P/B) Ratio | 2.08 | 1.15 | 1.22 | 1.21 | 1.95 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 24.98 | -207.21 | -40.07 | -15.83 | -29.73 |
| Price-to-Operating Cash Flow Ratio | 17.81 | 20.55 | 37.64 | -41.02 | -52.65 |
| Price-to-Earnings Growth (PEG) Ratio | 0.19 | -0.16 | 1.60 | 0.66 | -0.26 |
| Enterprise Value Multiple | 26.25 | 49.77 | -64.29 | -29.51 | -22.59 |
| Enterprise Value | 6.20B | 3.25B | 2.67B | 2.55B | 4.71B |
| EV to EBITDA | 26.25 | 49.77 | -64.29 | -29.51 | -22.59 |
| EV to Sales | 5.86 | 4.15 | 5.07 | 7.65 | 26.47 |
| EV to Free Cash Flow | 23.06 | -188.26 | -28.92 | -10.80 | -22.88 |
| EV to Operating Cash Flow | 16.44 | 18.67 | 27.17 | -27.97 | -40.52 |
| Tangible Book Value Per Share | 9.86 | 9.50 | 9.24 | 9.23 | 10.57 |
| Shareholders’ Equity Per Share | 9.99 | 9.59 | 9.27 | 9.37 | 10.67 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.03 | 0.00 | 0.00 | -0.06 | 0.07 |
| Revenue Per Share | 3.27 | 2.42 | 1.61 | 1.01 | 0.60 |
| Net Income Per Share | 0.76 | 0.31 | -0.24 | -0.34 | -0.68 |
| Tax Burden | 1.06 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.16 | 2.77 | 1.02 | 1.01 | 0.92 |
| Research & Development to Revenue | 0.23 | 0.30 | 0.49 | 0.70 | 0.94 |
| SG&A to Revenue | 0.30 | 0.34 | 0.22 | 0.33 | 0.57 |
| Stock-Based Compensation to Revenue | 0.00 | 0.03 | 0.16 | 0.26 | 0.43 |
| Income Quality | 1.58 | 1.74 | -1.25 | 0.80 | 0.58 |
Currency in CNY
